US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

27.79 -0.29 (-1.03%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amylyx Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
News headline image
AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Why Shares in Amylyx Pharmaceuticals Soared This Week ↗
Via The Motley Fool
News headline image
Amylyx Eyes $2B Opportunity In Post-Surgery Sugar Crash Market ↗
Guggenheim initiates Amylyx at Buy with $17 price forecast, citing PBH drug avexitide's Phase 3 potential and $2 billion+ market opportunity. 
Via Benzinga
News headline image
Carnival Posts Better-Than-Expected Earnings, Joins Liminatus Pharma, Coinbase Global, Uber And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
Exploring Amylyx Pharma's Earnings Expectations ↗
 
Via Benzinga
News headline image
This MakeMyTrip Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday ↗
 
Via Benzinga
News headline image
This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
4 Analysts Assess Amylyx Pharma: What You Need To Know ↗
 
Via Benzinga
News headline image
Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Lumentum Holdings To Rally Around 46%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
Amylyx Pharmaceuticals to Participate in Upcoming May Investor Conferences
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
This Logitech International Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday ↗
 
Via Benzinga
News headline image
Amylyx Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Earnings Scheduled For March 4, 2025 ↗
 
Via Benzinga
News headline image
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >